Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia

Reuters01-07

Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia

Rezolute Inc. has outlined progress in its late-stage rare disease programs targeting hyperinsulinism, a serious condition characterized by excessive insulin production leading to hypoglycemia. The company’s lead candidate, ersodetug (RZ358), is an antibody therapy being evaluated for both congenital and tumor-induced hyperinsulinism. Ersodetug has received Breakthrough Therapy Designation from the US FDA, PRIME designation from the European Medicines Agency, and Orphan Drug Designation in both the US and EU. Data from clinical trials and real-world use suggest activity against hypoglycemia in patients with hyperinsulinism. Rezolute plans to report topline data from a Phase 3 trial in tumor hyperinsulinism in the second half of 2026, with ongoing regulatory engagement for congenital hyperinsulinism. Current standard of care remains inadequate, as a significant portion of patients do not respond to existing therapies such as diazoxide and may experience serious side effects. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601830808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601830808","market":"nz","top_or_hot":-1,"title":"Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rezolute Inc. has outlined progress in its late-stage rare disease programs targeting hyperinsulinism, a serious condition characterized by excessive insulin production leading to hypoglycemia. The company’s lead candidate, ersodetug (RZ358), is an antibody therapy being evaluated for both congenital and tumor-induced hyperinsulinism. Ersodetug has received Breakthrough Therapy Designation from the US FDA, PRIME designation from the European Medicines Agency, and Orphan Drug Designation in both the US and EU. Data from clinical trials and real-world use suggest activity against hypoglycemia in patients with hyperinsulinism. Rezolute plans to report topline data from a Phase 3 trial in tumor hyperinsulinism in the second half of 2026, with ongoing regulatory engagement for congenital hyperinsulinism. Current standard of care remains inadequate, as a significant portion of patients do not respond to existing therapies such as diazoxide and may experience serious side effects. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rezolute Inc. has outlined progress in its late-stage rare disease programs targeting hyperinsulinism, a serious condition characterized by excessive insulin production leading to hypoglycemia. The company’s lead candidate, ersodetug (RZ358), is an antibody therapy being evaluated for both congenital and tumor-induced hyperinsulinism. Ersodetug has received Breakthrough Therapy Designation from the US FDA, PRIME designation from the European Medicines Agency, and Orphan Drug Designation in both the US and EU. Data from clinical trials and real-world use suggest activity against hypoglycemia in patients with hyperinsulinism. Rezolute plans to report topline data from a Phase 3 trial in tumor hyperinsulinism in the second half of 2026, with ongoing regulatory engagement for congenital hyperinsulinism. Current standard of care remains inadequate, as a significant portion of patients do not respond to existing therapies such as diazoxide and may experience serious side effects. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RZLT","symbol_name":"Rezolute, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6rBdF5:1","article_id":"2601830808","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601830808","pubTimestamp":1767788585,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rezolute Inc. has outlined progress in its late-stage rare disease programs targeting hyperinsulinism, a serious condition characterized by excessive insulin production leading to hypoglycemia. The company’s lead candidate, ersodetug , is an antibody therapy being evaluated for both congenital and tumor-induced hyperinsulinism. Ersodetug has received Breakthrough Therapy Designation from the US FDA, PRIME designation from the European Medicines Agency, and Orphan Drug Designation in both the US and EU. Data from clinical trials and real-world use suggest activity against hypoglycemia in patients with hyperinsulinism. Rezolute plans to report topline data from a Phase 3 trial in tumor hyperinsulinism in the second half of 2026, with ongoing regulatory engagement for congenital hyperinsulinism. Current standard of care remains inadequate, as a significant portion of patients do not respond to existing therapies such as diazoxide and may experience serious side effects. You can access the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RZLT":"Rezolute, Inc.","BK4139":"生物科技"},"translate_title":"Rezolute Inc.推出高胰岛素血症和低血糖症晚期治疗演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia\n    \n\n        Rezolute Inc. has outlined progress in its late-stage rare disease programs targeting hyperinsulinism, a serious condition characterized by excessive insulin production leading to hypoglycemia. The company’s lead candidate, ersodetug (RZ358), is an antibody therapy being evaluated for both congenital and tumor-induced hyperinsulinism. Ersodetug has received Breakthrough Therapy Designation from the US FDA, PRIME designation from the European Medicines Agency, and Orphan Drug Designation in both the US and EU. Data from clinical trials and real-world use suggest activity against hypoglycemia in patients with hyperinsulinism. Rezolute plans to report topline data from a Phase 3 trial in tumor hyperinsulinism in the second half of 2026, with ongoing regulatory engagement for congenital hyperinsulinism. Current standard of care remains inadequate, as a significant portion of patients do not respond to existing therapies such as diazoxide and may experience serious side effects. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601830808","isCrawlerRequest":true}